GlaxoSmithKline Acknowledges Misrepresentation in Scientific Article - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

GlaxoSmithKline Acknowledges Misrepresentation in Scientific Article
One employee is dismissed, another has resigned, and three others are put on administrative leave.

GlaxoSmithKline (GSK) issued a statement to say it and the scientific publication Nature Medicine recently became aware of allegations of misrepresentation of data in a research paper written by scientists at GSK’s China research center and published in Nature Medicine in 2010 (1). The published study was from preclinical, early-stage research and did not directly involve patients, according to GSK. The article examined the role of interleukin-7 in T helper type 17 cell survival and expansion in treating autoimmune disease.

“The integrity of our research is critical to our work and when these allegations came to light, we immediately contacted the journal to tell them that we were taking the charges seriously and would be investigating thoroughly,” said GSK in the statement. “Regretfully, our investigation has established that certain data in the paper were indeed misrepresented. We’ve shared our conclusion that the paper should be retracted and are in the process of asking all of the authors to sign a statement to that effect, according to Nature Medicine’s procedure.”

GSK says that one individual has been dismissed from GSK, a second has submitted his resignation, and three others have been placed on administrative leave, pending a final review. “We are committed to the highest ethical and scientific standards and regulators, physicians, and patients can have confidence in the research we carry out.” said GSK in its statement.

Reference 1. X. Liu et al., Nature Medicine 16 (2), 191-197 (2010).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here